OverviewSuggest Edit

Bluebird Bio is a clinical-stage biotechnology company that develops transformative gene therapies for severe genetic diseases and cancer. The Company's clinical programs in severe genetic diseases include LentiGlobin product candidate to treat transfusion dependent β-thalassemia and to treat severe sickle cell disease and itsLenti-D product candidate to treat cerebral adrenoleukodystrophy.

TypePublic
Founded1992
HQCambridge, MA, US
Websitebluebirdbio.com
Employee Ratings3.2

Latest Updates

Employees (est.) (Jan 2020)1,090(+8%)
Job Openings102
Revenue (FY, 2020)$250.7 M(+462%)
Share Price (May 2021)$30.5(+3%)

Key People/Management at Bluebird Bio

Derek Adams

Derek Adams

Chief Technology & Manufacturing Officer
Jenn Snyder

Jenn Snyder

VP, Corporate Communications
Jason F. Cole

Jason F. Cole

Chief Operating & Legal Officer
Ingrid Goldberg

Ingrid Goldberg

VP, Investor Relations
Chip Baird

Chip Baird

Chief Financial Officer
Elizabeth Pingpank

Elizabeth Pingpank

Director, Investor Relations
Show more

Bluebird Bio Office Locations

Bluebird Bio has offices in Cambridge, Durham and Seattle
Cambridge, MA, US (HQ)
60 Binney St
Durham, NC, US
1733 TW Alexander Dr
Seattle, WA, US
188 E Blaine St #300
Show all (3)

Bluebird Bio Financials and Metrics

Bluebird Bio Revenue

Bluebird Bio's revenue was reported to be $250.73 m in FY, 2020
USD

Revenue (FY, 2020)

250.7m

Gross profit (FY, 2020)

245.3m

Gross profit margin (FY, 2020), %

97.8%

Net income (FY, 2020)

(622.3m)

EBIT (FY, 2020)

(623.0m)

Market capitalization (7-May-2021)

2.1b

Closing stock price (7-May-2021)

30.5

Cash (31-Dec-2020)

317.7m

EV

1.9b
Bluebird Bio's current market capitalization is $2.1 b.
Annual
USDFY, 2013FY, 2014Y, 2014FY, 2015Y, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

20.2m25.4m25.4m14.1m14.1m6.2m35.4m54.6m44.7m250.7m

Revenue growth, %

26%(45%)(56%)

Cost of goods sold

885.0k3.0m5.4m

Gross profit

53.7m41.7m245.3m
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

6.3m6.4m6.3m6.3m6.4m6.3m4.9m1.3m1.5m1.6m1.6m6.8m16.7m7.7m16.0m7.9m11.5m12.5m13.3m8.9m21.9m78.4m13.4m

Cost of goods sold

21.0k29.0k430.0k613.0k862.0k1.0m

Gross profit

7.8m11.5m12.0m12.7m8.0m20.8m

Gross profit Margin, %

100%100%97%95%90%95%
USDQ2, 2013

Financial Leverage

1.5 x
Show all financial metrics

Bluebird Bio Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Bluebird Bio Online and Social Media Presence

Embed Graph

Bluebird Bio Company Culture

  • CEO Rating

    F

    50/100

Learn more on Comparably

Bluebird Bio News and Updates

Insights on the Advanced Therapy Medicinal Products Global Market to 2027 - Featuring Bluebird Bio, Celgene and Gilead Lifesciences Among Others

DUBLIN, April 26, 2021 /PRNewswire/ -- The "Advanced Therapy Medicinal Products - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Amid the COVID-19 crisis, the global market for Advanced Therapy Medicinal Products estimated at US$3.6...

Portnoy Law: Lawsuit Filed On Behalf of Bluebird Bio Inc. Investors

Click here to join the case​

Bluebird Bio shares slide 34% after company suspends trials of sickle cell disease treatment

Shares of Bluebird Bio Inc. slid 34% in premarket trade Tuesday, after the biotech said it is temporarily suspending Phase 1/2 and Phase 3 trials of its LentiGlobin gene therapy for sickle cell disease after a report of a suspected unexpected serious adverse reaction of acute myeloid leukemia. The …

What Bluebird Bio Gets Wrong In Pricing For Its $1.8 Million Drug

By enacting the above suggestions, Bluebird Bio can show that it is confident in its product, that it will only get paid if the product works, that it will adjust costs if there is a need for future treatments and that it won’t be opportunistic in taking annual price hikes.

Brainstorm Health: GSK Tesaro Deal, VR Medical Education, Bluebird Bio

Brainstorm Health Daily: December 1, 2018

Gene Therapy Market to Set Phenomenal Growth from 2018 to 2026 Estimated by Global Top Players GlaxoSmithKline plc, Bluebird Bio, Inc., Adaptimmune Therapeutics plc, Celgene Corporation, Shanghai Sunway Biotech Co. Ltd., Merck KGaA, Transgene SA

#Summary: Summary This report includes market status and forecast of global and major regions, with the introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. Posted via Industry Today. Follow us on Twi…
Show more

Bluebird Bio Frequently Asked Questions

  • When was Bluebird Bio founded?

    Bluebird Bio was founded in 1992.

  • Who are Bluebird Bio key executives?

    Bluebird Bio's key executives are Derek Adams, Jenn Snyder and Jason F. Cole.

  • How many employees does Bluebird Bio have?

    Bluebird Bio has 1,090 employees.

  • What is Bluebird Bio revenue?

    Latest Bluebird Bio annual revenue is $250.7 m.

  • What is Bluebird Bio revenue per employee?

    Latest Bluebird Bio revenue per employee is $230 k.

  • Who are Bluebird Bio competitors?

    Competitors of Bluebird Bio include Genprex, Bellicum Pharmaceuticals and Modis Therapeutics.

  • Where is Bluebird Bio headquarters?

    Bluebird Bio headquarters is located at 60 Binney St, Cambridge.

  • Where are Bluebird Bio offices?

    Bluebird Bio has offices in Cambridge, Durham and Seattle.

  • How many offices does Bluebird Bio have?

    Bluebird Bio has 3 offices.